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Abstract
The contribution of inflammation to neurodegenerative diseases is increasingly recognized, but the role of
inflammation in sporadic amyotrophic lateral sclerosis (sALS) is not well understood and no animal model is avail-
able. We used enzyme-linked immunosorbent assays (ELISAs) to measure the cytokine interleukin-17A (IL-17A) in
the serum of ALS patients (n = 32; 28 sporadic ALS (sALS) and 4 familial ALS (fALS)) and control subjects (n = 14;
10 healthy subjects and 4 with autoimmune disorders). IL-17A serum concentrations were 5767 ± 2700 pg/ml
(mean ± SEM) in sALS patients and 937 ± 927 pg/ml in fALS patients in comparison to 7 ± 2 pg/ml in control sub-
jects without autoimmune disorders (p = 0.008 ALS patients vs. control subjects by Mann-Whitney test). Sixty-four
percent of patients and no control subjects had IL-17A serum concentrations > 50 pg/ml (p = 0.003 ALS patients
vs. healthy subjects by Fisher’s exact test). The spinal cords of sALS (n = 8), but not control subjects (n = 4), were
infiltrated by interleukin-1b- (IL-1b-), and tumor necrosis factor-a-positive macrophages (co-localizing with neurons),
IL-17A-positive CD8 cells, and IL-17A-positive mast cells. Mononuclear cells treated with aggregated forms of wild
type superoxide dismutase-1 (SOD-1) showed induction of the cytokines IL-1b, interleukin-6 (IL-6), and interleukin-
23 (IL-23) that may be responsible for induction of IL-17A. In a microarray analysis of 28,869 genes, stimulation of
peripheral blood mononuclear cells by mutant superoxide dismutase-1 induced four-fold higher transcripts of inter-
leukin-1a (IL-1a), IL-6, CCL20, matrix metallopeptidase 1, and tissue factor pathway inhibitor 2 in mononuclear cells
of patients as compared to controls, whereas the anti-inflammatory cytokine interleukin-10 (IL-10) was increased in
mononuclear cells of control subjects. Aggregated wild type SOD-1 in sALS neurons could induce in mononuclear
cells the cytokines inducing chronic inflammation in sALS spinal cord, in particular IL-6 and IL-17A, damaging neu-
rons. Immune modulation of chronic inflammation may be a new approach to sALS.
Background
Amyotrophic lateral sclerosis (ALS) is a paralyzing neu-
rodegenerative disease, characterized by the loss of
upper and lower motor neurons. A majority of cases are
sporadic (sALS) and their cause remains unknown. Less
than 10% of ALS cases are familial (fALS) with 20% of
these cases linked to various mutations in the Cu/Zn
mutant superoxide dismutase 1 (SOD-1) gene [1]. SOD-
1 is an ubiquitous small cytosolic metalloenzyme that
catalyzes the conversion of superoxide anions to
hydrogen peroxide [2]. A subset of familial ALS cases is
characterized by mutant SOD-1 protein aggregates in
neuronal inclusions [3], which have toxic properties and
occur selectively in motor neurons. Recently, inclusions
with misfolded SOD-1 forms [4] and a wild-type SOD-1
sharing aberrant conformation and pathogenic pathway
with mutant SOD-1 [5] have also been identified in
sporadic ALS spinal cord motor neurons, suggesting the
possibility that misfolded SOD-1 auto antigens stimulate
inflammation in sporadic ALS as well.
SOD-1 mutations have diverse effects on the structure,
functional activity and native stability of SOD-1, but a
common pathway has been proposed through the for-
mation of SOD-1 aggregates in the spinal cords of
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dence suggests that protein misfolding and aggregation
might be a common pathophysiologic link between
sALS and fALS. In symptomatic transgenic mice that
over express mutant SOD-1, a number of misfolded
forms of SOD-1 are present in the spinal cords includ-
ing those that expose regions of SOD-1 normally buried
such as the dimer interface, and some of these forms
have been found in patients. An altered SOD-1 species
was found within the anterior horns of sALS patients
that likely originated from misfolded wild type SOD-1
[7], and oxidation of wild type SOD-1 produced a mis-
folded protein with toxic properties of mutant SOD-1
[8]. Recently, abnormally folded SOD-1 has been
detected in the spinal cord inclusions of a subset of
sALS patients [4]. Structural studies of the inclusions
found in the spinal cords of transgenic ALS mice show
that they are largely composed of SOD-1 fibrils [9,10].
These forms likely occur due to a lack of bound metal
cofactors, such as copper and/or zinc, and the normal
inter subunit disulfide bond, the posttranslational modi-
fications that are critical for the exceptionally high stabi-
lity and solubility of SOD-1. Soluble SOD-1, upon
removal of bound metals, can be rapidly converted to
amyloid fibrils by the reduction of the intramolecular
disulfide bond, even in a small fraction of the protein
[11].
Increased serum and CSF concentrations of cytokines
in neurodegenerative diseases, such as Huntington dis-
ease [12] and Parkinson disease [13], are considered
important in the disease pathogenesis even before the
disease onset. In addition, non-neuronal glial cells con-
tribute to ALS disease mechanisms [14], which is sup-
ported by transgenic mouse studies. Inflammatory
cytokines, prostaglandin E2 and leukotriene B4, induci-
ble nitric oxide synthase and NO were found in astro-
cytes from the G93A-SOD-1 mouse, an important
model of human fALS [15]. Furthermore, adult micro-
glia from mutant SOD-1 transgenic mice released tumor
necrosis factor-alpha [16], which may stimulate IL-6
production from astrocytes and microglia leading to
reactive gliosis in pathophysiological processes in the
CNS [17]. However, the role of cytokines is not well
understood in sALS patients, although previous studies
highlighted a number of abnormal chemokines and
cytokines, including CCL2 (MCP-1), interleukin-6 (IL-
6), tumor necrosis factor-a (TNF-a), and recently, inter-
leukin-17 (IL-17) and interleukin-23 (IL-23) in patients
[18]. As recently suggested [19], some of these immune
factors such as IL-6, and interleukin-13 (IL-13) positive
T-cells, and IL-17A described herein, may be also useful
as blood biomarkers for ALS.
The active role played by the immune system in ALS
is revealed by the disrupted blood-brain barrier and the
presence of activated macrophages, microglia, dendritic
cells, T cells and mast cells in the spinal cord of ALS
patients [20,21]. Positron emission studies show micro-
glial activation during all stages of the disease in the
motor cortex and other areas of the brain correlating
w i t hd i s e a s es e v e r i t y[ 2 2 ] .T r a n s g e n i cm i c ee x p r e s s i n g
mutant SOD-1 also show evidence of extensive micro-
glial activation, such as the increased expression of
pro-inflammatory factors including transforming growth
factor-b1, TNF-a and macrophage-colony stimulating
factor [23]. Therefore, the pathway by which misfolded
or aggregated SOD-1 triggers an inflammatory response
is crucial to the role of inflammation in ALS.
Here, we report the cytokines induced by wild type
and mutant SOD-1 proteins in peripheral blood mono-
nuclear cells of ALS patients and extend the relevance
of these studies by examining the immunopathology in
the spinal cord of confirmed ALS patients (deceased).
To our knowledge, these studies are the first to investi-
gate how aggregated WT SOD-1 can trigger IL-1b,I L - 6
and IL-23 responses in human mononuclear cells, the
cytokines participating in the induction of IL-17A. Our
results suggest that the activation of chronic inflamma-
tion, including the IL-17A mediated pathway, a signa-
ture of autoimmune diseases such as multiple sclerosis
[24], is also critical in ALS.
Methods
Study population
Blood specimens for cytokine testing were obtained
under UCLA Institutional Review Board-approved pro-
tocols. Written informed consent was obtained from all
patients or their representatives according to the
Declaration of Helsinki. 32 ALS patients, 28 with spora-
dic ALS (mean age 57.8 years) and 4 familial ALS sub-
jects, who do not have a known SOD-1 mutation (mean
age 67 years), 10 normal controls (mean age 56.6 years),
and 4 subjects with autoimmune disease (mean age 58.7
years) were enrolled in this study via the UCLA ALS
clinic (Table 1). The patients were diagnosed as prob-
able or definite ALS by the revised EL Escorial criteria
[25] and electromyography. The mean score of the ALS
functional rating scale of sALS patients was 32.3 ± 2.1
months and mean disease duration was 24.5 ± 3
months.
Spinal cord tissues and fluid
Immunohistochemistry was performed on paraffin-
embedded thoracic spinal cord tissues of 8 sporadic
ALS patients, 3 Alzheimer disease patients and 4 other
subjects without neuropathology (Table 2), which were
provided by the UCLA Brain Bank (four ALS, 3 Alzhei-
mer disease, and 1 case without neuropathology) and
the UCLA National Neurological AIDS Bank (NNAB)
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UCLA NNAB also provided frozen lumbar and thoracic
spinal cord sections of 3 ALS patients and 3 control
non-ALS subjects without neuropathology.
Immunohistochemistry and immunofluorescence
Paraffin-embedded sections were deparaffinized, peroxi-
dase activity was blocked with 3% hydrogen peroxide in
methanol for 10 min, and subjected to heat-induced
antigen retrieval at 95°C for 25 min. After dual endo-
genous enzyme block, they were stained by primary and
secondary antibodies using Dakocytomation Envision⊕
System. Frozen sections were fixed with 4% paraformal-
dehyde, permeabilized with 1% Triton X-100, blocked
with 1% bovine serum albumin, incubated with primary
antibodies overnight at 4°C and secondary antibodies for
1 h at 37°C [26]. Primary antibodies were rabbit or
mouse anti-CD3, anti-CD4, anti-CD8, anti-CD68
(Dako), goat anti-IL-1b (Santa Cruz), goat anti-caspase 3
(Santa Cruz), mouse anti-IL-6 (Cymbus), mouse anti-IL-
10 (DNAX), mouse anti-IL-17A (R&D Systems), goat
anti-IL-17A (C20) (Santa Cruz), mouse anti-TNF-a
(SantaCruz), mouse monoclonal anti-mast cell tryptase,
clone AA1 (DakoCytomation), mouse anti-granzyme B,
clone GrB-7(Chemicon), normal mouse or goat IgG.
Secondary anti-mouse, anti-rabbit, or anti-goat antibo-
dies were ALEXA-595 or ALEXA-488-conjugated (Invi-
trogen). Phalloidin was FITC or TRITC conjugated
(Sigma). The preparations were independently examined
by two observers (MF and GL) using the Olympus
Research microscope with Hamamatsu camera or using
Leica SP5X White Light Laser Confocal microscope.
SOD-1 protein preparation and fibrillation
Wild-type and mutant SOD-1 (G37R, G93A, D101N)
were expressed in Saccharomyces cerevisae and purified
using a combination of ammonium sulfate precipitation
and hydrophobic interaction, ion exchange and size
exclusion chromatography on Sephadex G75 column
[27,28,11].. Purified SOD1, also known as “As-isolated
SOD1” (AI SOD-1), was demetallated to generate APO-
SOD-1using multiple rounds of dialysis against EDTA.
The metal content of APO- and AI- SOD1 was verified
by Inductively-coupled plasma mass spectrometry (ICP-
MS). Typically, AI SOD1 contained 2.5 equivalents of
zinc and 0.5 equivalents of copper, while APO-SOD-
Table 1 Demographic and cytokine information
sALS fALS Control Autoimmune disorder
a
n 28 4 10 4
Age (years) 57.8 (2.5) 67.0 (4.7) 56.6 (9.6) 58.7 (13.0)
M/F ratio 14/14 2/2 7/3 4/0
Duration (months) 24.5 (3.0) 16.0 (4.2) N/A N/A
FRS 32.3 (2.1) 31.5 (2.7) N/A N/A
IL-17A
b 64.2%* 75.0% 0.0%* 100.0%
IL-17A
c 5767.4 (2700.4) 937.3 (927.8) 7 (4.8) 9993.6 (1865.5)
IL-17A
d 1145.4 (317.9)
+ 984 (581.6) 6.7 (2.1)
+ 2815 (861.7)
IL-17A
e 1126.0 (320.1)
+ 1124.0 (594.9) 7.1 (2.4)
+ 2074.0 (709.8)
Data are expressed as mean (± standard error of mean)
a Patients with eczema or asthma
b IL-17% positive in the serum (sALS vs. healthy controls, p = 0.003)
c IL-17 (pg/mL) serum level (ALS patients vs. normal controls, p = 0.008)
d IL-17 (pg/mL) PBMC supernatant level (without stimulation)
e IL-17 (pg/mL) PBMC supernatant level (with stimulation by fibrillar WT SOD-1 (2 μg/mL))
* p < 0.003 sALS vs. control
+ p < 0.01 sALS vs. control
Table 2 Demographic and diagnostic data of deceased
patient providing spinal cord tissues
Subject Age (at
death)
Sex Pathological Diagnosis
1 75 years female Sporadic amyotrophic lateral sclerosis
2 83 years male Sporadic amyotrophic lateral sclerosis
3 83 years male Sporadic amyotrophic lateral sclerosis
4 50 years male Sporadic amyotrophic lateral sclerosis
5 66 years male Sporadic amyotrophic lateral sclerosis
6 64 years female Sporadic amyotrophic lateral sclerosis
7 64 years female Sporadic amyotrophic lateral sclerosis
8 54 years male Sporadic amyotrophic lateral sclerosis
9 67 years male Alzheimer disease, Braak stage VI
10 90 years male Braak stage VI
11 76 years male Braak stage I
12 37 years male Angiosarcoma of pleura, no
metastases
13 78 years male No neuropathology
14 62 years female No neuropathology
15 46 years Male No neuropathology
Fiala et al. Journal of Neuroinflammation 2010, 7:76
http://www.jneuroinflammation.com/content/7/1/76
Page 3 of 141contained 0.5-0.8 equivalents of each metal per dimer.
To convert apo-SOD-1 to fibrils, 50 μMp r o t e i nw a s
incubated in 10 mM potassium phosphate (pH 7) and 5
mM DTT in a total volume of 200 μL in a chamber of a
96-well plate, including a polytetrafluoroethylene (PTFE)
ball (1/8 inch diameter) and 40 μMt h i o f l a v i nT[ 1 1 ] .
The cytokine and plate was constantly agitated in a
Fluoroskan microplate instrument (Thermo) at 37°C
and fibril formation was monitored by thioflavin T
fluorescence using lex of 444 nm and lem of 485 nm.
Fibril formation was indicated by a sigmoidal growth in
fluorescence and verified by electron microscopy. For
co-incubation with PBMC’s, the SOD1 fibrils were pre-
cipitated by centrifugation at 16,000g for 15 minutes
and resuspended in 10 mM potassium phosphate at pH
7. In some cases, fibrils were sonicated for 10 minutes
in a bath sonicator at room temperature. To exclude
contamination with endotoxin, endotoxin concentrations
were determined using the Limulus amebocyte lysate
assay (LAL assay) (Associates of Cape Cod) by a quanti-
tative kinetic assay. The endotoxin levels, 0.0448 ±
0.0000 pg/ml in the wild type superoxide dismutase 1,
and 0.32 ± 0.08 pg/ml in the G37R superoxide dismu-
tase 1, were below the concentrations active as a
pyrogen.
Cytokine assays in fluids
Peripheral blood mononuclear cells were separated from
heparin-anaticoagulated blood by Ficoll-Hypaque gradi-
ent centrifugation. The supernatant media of overnight
cultures stimulated using the indicated SOD-1 protein
(2 μg/ml), amyloid-b 1-42 (2 μg/ml) or medium with
DMSO (1:1,000) were tested by multiplexed bioassays
for human cytokines, the High Sensitivity Human Cyto-
kine Panel - Pre-mixed 13 Plex (Millipore). The Lumi-
nex-platform assay panel simultaneously quantified
supernatant concentrations of human IL-1b, interleukin-
2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), IL-6,
interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-10
(IL-10), interleukin-12 (IL-12), IL-13, interferon-g, gran-
ulocyte-macrophage colony stimulating factor, TNF-a.
Assay results, expressed in pg/ml, were obtained using a
Bio-RAD BioPlex 200 dual laser, flow-based sorting and
detection analyzer. IL-17A cytokine was assayed in per-
ipheral blood mononuclear cell supernatant and serum
by a human-specific ELISA (DuoSet) kit (R&D Systems).
IL-23 was assayed by the Human IL-23 immunoassay
(R&D Systems).
Whole-genome expression analysis was performed
with the Affymetrix Gene Array ST 1.0. RNA from each
sample was prepared using manufacturer recommended
protocols and the Qiagen RNAEasy columns. Each sam-
ple was labeled using standard protocols and reagents
from Affymetrix. Probes were fragmented and hybridized
to the Affymetrix Human Gene 1.0 ST Array. Raw cel
files generated from the Affymetrix Expression Console
software were loaded into GeneSpring GX 10.0.2 soft-
ware (Agilent) for analysis. We used the Robust Multi-
array Analysis (RMA) probe summarization algorithm,
with a transcript level of CORE.
Statistical testing was performed using the statistical
software SPSS, Version 10.0, as follows: IL-17A in
serum and IL-23 by non-parametric Mann-Whitney and
Wilcoxon tests; supernatant cytokines by paired t-test
analysis; the proportion of positive tests by the Fisher’s
exact test.
Results
Interleukin-17A in the blood of ALS patients
The cytokine concentrations of IL-17A were assayed in
28 sporadic and 4 familial ALS patients, 10 normal con-
trol subjects, and 4 subjects suffering from episodes of
eczema or asthma. Mean IL-17A serum concentrations
of sALS patients (5767 ± 2700 pg/ml) were significantly
higher (p = 0.008 by Mann-Whitney and Wilcoxon
tests) than those in normal controls without autoim-
mune manifestations (7 ± 4.8 pg/ml) (Table 1). Mean
IL-17A serum concentrations in fALS patients were 937
± 927 pg/ml. The level of IL-17A was increased above
the highest observed level in control subjects of 40 pg/
ml in 64% of sALS patients, 75% fALS patients, 100%
subjects with immune disorders and 0% normal controls
(p = 0.003 sALS vs. healthy controls). The production of
IL-17A in sALS PBMC’s was constitutive, i.e., unlike
other cytokines, it was not increased by SOD-1 stimula-
tion over 18 hr: not stimulated 1145 ± 317.9 pg/ml;
stimulated with fibrillar wild type SOD-1, 1,126 ±
320 pg/ml. In a cross-sectional analysis, IL-17 concentra-
tions were highest in early patients and appeared to
decrease with duration of illness and FRS (N.S.) (Figure
1A, B). However, the serum and PBMC supernatant con-
centrations of IL-17A in two patients followed over three
months appeared to be fluctuating (data not shown).
Immunopathology of the ALS spinal cord
T cells, macrophages/microglia and mast cells were the
immune cells found in ALS and control spinal cords.
The ALS spinal cord was infiltrated in patchy fashion by
T cells and mast cells in the gray matter, and diffusely
by macrophages/microglia in the gray and white matter
(Figure 2).
In the gray matter, IL-17A was expressed in patchy
fashion on several cell types: (1) CD8-positive CD3-posi-
tive T cells, (2) CD8-negative CD3-positive T cells, (3)
mast cell tryptase-positive mast cells. Some CD3 cells
expressed granzyme B or caspase-3 (Figure 3).
The gray and the white matter were diffusely infil-
trated by CD68-positive macrophages/microglia. These
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and many co-localized with neurons (Figure 5).
In summary: Two observers examined 87 slides
stained by CD3, CD8, IL-17A, CD68, IL-1b,T N F - a and
mast cell tryptase antibodies. IL-17A/CD3 T cells were
found in five of 8 ALS spinal cords but not in any AD
or control spinal cords; macrophages in 4 ALS spinal
cords and two AD spinal cords; and mast cells in two
ALS and three AD spinal cords (Figure 2U).
Induction of IL-1b, IL-6 and IL-23 cytokines by fibrillar
wild type and mutant SOD-1
To clarify whether certain physical forms of SOD-1
could induce the cytokines IL-1b, IL-6 and IL-23, which
can polarize T cells into the TH17 subset, we tested
their induction by three forms of wild type and mutant
SOD-1: as-isolated (AI), demetallated (APO), and fibril-
lar (Figure 6). These preparations had no significant
levels of endotoxin (see Methods). IL-1b and IL-6 are
Figure 1 Relation of blood IL-17A levels to disease duration and ALS functional rating scale (FRS). (A) Duration vs. log IL-17, correlation =
-0.16, p = 0.38. (B) FRS vs. log IL-17, correlation = 0.23, p = 0.22.
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tion by different physical forms of SOD-1 identifies
these forms as responsible for inflammation. The dose-
response experiment with PBMC’so ft w oA L Sp a t i e n t s
and the wild type SOD-1 proteins showed induction by
the fibrillar and APo forms, but not the AI form; and
the experiment with the G37R and D101N SOD-1
mutant SOD-1 proteins, showed induction by the AI
and APO forms, but not the fibrillar form.
IL-23 production was increased by stimulation with
fibrillar SOD-1 of ALS patients’ PBMC’s (n = 6; mean ±
S.E.M; not stimulated 52 ± 11.2 pg/ml, stimulated 123 ±
24.5 pg/ml; Wilcoxon p value = 0.0156) and control
subjects’ PBMC’s (n = 3; mean ± S.E.M; not stimulated
Figure 2 IL-17A/CD8 T cells and TNF-a/CD68 cells infiltrate ALS spinal cord tissues. Sections of thoracic spinal cord of five ALS patients
(At oJ ) and 5 control subjects (two Alzheimer disease patients (K, L, P, Q) and 3 patients without neurological disease (M, N, O, R, S, T) were
stained by CD8 antibody (At oE ) , CD3 antibody (K to O) and CD68 antibody (F to J; P to T) using immunohistochemistry (IHC) (A, B, F, G, K,
L, P, Q) or immunofluorescence (IFA) (C, D, E, H, I, J, M, N, O, R, S, T). The significant results were: 1. CD8 in ALS gray matter: focal aggregates
of IL-17A/CD8 T cells (red/brown by IHC (A, B) and red/green by IFA (C, D, E)) in 4/8 ALS spinal cords; 2. CD68 in ALS gray and white matter:
diffuse infiltration by TNF-a/CD68 cells (red/brown by IHC (F, G), and red/green by IFA (H, I, J)) in 4/8 ALS spinal cords; 3. CD3 in control gray
matter: Lack of IL-17A on CD3 cells (no red staining by IHC (K, L) and IFA (M, N, O)) in 3 AD and 4 control spinal cords; 4. CD68 in control gray
and white matter: No TNF-a on CD68 cells (no red staining by IHC (P, Q), and IFA (R, S, T) in 3 control spinal cords; IL-17A/mast cell tryptase-
positive cells (Fig. 4E) were found in three of 5 ALS and 3 of 3 AD spinal cords. Staining experiments with normal mouse or goat IgG and a
secondary antibody were negative with all specimens.
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p = .1) (data not shown).
To clarify the spectrum of cytokine responses in ALS
patients, we tested induction of 13 supernatant cyto-
kines in a sample of 29 patients by sham, amyloid-b,
AI and fibrillar forms of wild type SOD-1, and the AI
form of G37R SOD-1. The fibrillar wild type SOD-1
a n dA IG 3 7 RS O D - 1 ,b u tn o tA b or AI wild type
SOD-1, significantly increased six of the 13 tested
cytokines in the supernatant media: IL-1b,I L - 6 ,I L - 7 ,
TNF-a, granulocyte-macrophage colony stimulating
factor, and IL-10 (Figure 7). Stimulation of control
PBMC’s with SOD-1 forms induced the same six cyto-
kines (data not shown).
Transcriptional stimulation by SOD-1 increases
inflammatory cytokines in patients and the anti-
inflammatory cytokine IL-10 in control subjects
The responses to mutant SOD-1 were analyzed at the
transcriptional level by microarray hybridization. The
analysis of 28,869 transcript cluster identifications in
peripheral blood mononuclear cells of 2 controls and 3
patients (stimulated 18 hr by mutant SOD-1) showed
strong stimulation of 7 cytokines (IL-10, IL-23A, granu-
locyte macrophage colony stimulating factor, IL-1b,
IL-1a, IL-6 and IL-7) in both patients and control sub-
jects (Figure 8). Of these, the increase in transcription of
IL-1a and IL-6 was ~ four-fold higher in patients com-
pared to controls. In agreement with the constitutive
production of IL-17A, its mRNA was not stimulated by
G37R SOD-1. The chemokines CCL2, CXCL1, CXCL2,
a n dC X C L 3w e r et r a n s c r i b e da tah i g hl e v e li np a t i e n t s
as well as controls at baseline and after stimulation.
G37R SOD-1 stimulated more CCL20 (5.5 fold), matrix
metallopeptidase 1 (4.5fold), and tissue factor pathway
inhibitor 2 (11.7 fold) in PBMC’s of patients, as com-
pared to control subjects. On the other hand, the anti-
inflammatory cytokine IL-10 mRNA was stimulated
more (2.0 fold) in PBMC’s of control subjects, as com-
pared to patients.
Discussion
Our results show that, in a cross-sectional study, 64% of
sALS and fALS subjects have strongly increased serum
concentrations of the cytokine IL-17A, compared to
normal subjects, and the concentrations of IL-17A fluc-
tuate, which could result in false-negative results in
some subjects. The spinal cord of deceased sALS
patients show a milieu in which polarization of CD3
cells to IL-17A-producing cells can develop in response
to products of macrophages, T cells and mast cells;
including IL-1b,T N F - a, IL-6, IL-23, and probably eico-
sanoids (Figure 2 and 6). The cytokine IL-17A is patho-
genic in inflammatory and autoimmune diseases such as
multiple sclerosis [24], psoriasis, inflammatory bowel
disease, systemic lupus erythematosus, and rheumatoid
arthritis [29]. CD8 cells in gray matter might have a role
in tissue destruction by cytotoxic cytokines, the cyto-
t o x i cm o l e c u l e sg r a n z y m eB ,a n dn i t r i co x i d e( N O ) ,
resembling the role of CD8 cells in multiple sclerosis
[24]. Although IL-17A is expressed on CD4 cells in the
animal model of multiple sclerosis, experimental allergic
encephalitis [24], IL-17A is expressed also on other
cells, such as macrophages in asthma [30], CD8 cells in
Behcet disease and psoriasis [31], and mast cells in
rheumatoid arthritis synovium.
The ALS spinal cord is infiltrated by IL-17A-positive
T cells and IL-17A-positive mast cells in gray matter
and by TNF-a-positive macrophages/microglia in gray
Figure 3 IL-17A-positive cells are CD3 cells and mast cells
localized in gray matter; CD3 T cells express granzyme B and
caspase-3. Immunohistochemistry (A, E) and immunofluorescence
(B, C, D).( A) IL-17A-positive cells (indicated by*) in the gray matter;
(B) Granzyme B/CD3 (red/green); (C) caspase-3/CD3 (red/green);
(D) IL-17A/CD3 (red/green); (E) IL-17A/mast cell tryptase-positive
mast cells (red/brown).
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were found to co-localize with neurons, reminiscent of
previously demonstrated large phagocytic cells sur-
rounding atrophic neurons [32]. Although the identifica-
tion of these cells as macrophages or microglia is not
possible since both are CD68-positive, blood-derived
macrophages may penetrate into the ALS spinal cord, as
suggested by their presence around the vessels with dis-
rupted ZO-1 junctions [32], and into Alzheimer disease
brain, as shown by their invasion across brain endothe-
lial cells with disrupted ZO-1 junction [33].
To clarify the induction of IL-17A in ALS patients, we
f o c u s e da t t e n t i o no nI L - 1 b, IL-6 [34], and IL-23, which
are known to induce IL-17A and can be produced by
macrophages and/or dendritic cells (Figure 6). The
development of IL-17A-producing TH17 cells is
initiated by transforming growth factor-b and IL-6,
which induce phosphor-STAT-3 and the transcription
factor RORgt, and is stabilized and expanded by the
cytokines IL-21 and IL-23 [35,36]. Human TH17 cell
differentiation requires IL-6, IL-1b and IL-21 or IL-23
[37]. In human studies, transforming growth factor-b
has not been found to be essential [38]. In a recent
mouse study, TH17 cells, which were induced by IL-1b,
I L - 6a n dI L - 2 3 ,w e r em o r ep a t h o g e n i ct h a nt h o s e
induced in presence of transforming growth factor-b
[39]. The cytokines and chemokines required for TH17
polarization, IL-1a,I L - 6 ,a n dC C L 2 0 ,a n dm a t r i x
Figure 4 IL-1b/CD68 macrophages infiltrate both the gray and the white matter of the ALS spinal cord. Immunohistochemistry (A);
immunofluorescence (B, C). (A) IL-1b/CD68 (red/brown) macrophages in the gray and the white matter; (B, C) IL-1b/CD68 (red/green)
macrophages.
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Page 8 of 14metalloproteinase 1, were transcriptionally stimulated
more in ALS patients than in controls (Figure 8).
The presence of IL-17A in mast cells in the spinal
cord of patients with ALS and Alzheimer disease (Figure
3) has not been previously reported. Mast cells together
with macrophages produce eicosanoids [40], which are
important in polarization of the TH17 subset [41]. Mast
cells are emerging as master regulators with bi-func-
tional role in both innate and adaptive immunity [42].
In the setting of autoimmunity, mast cells have a role in
the initiation of the pathological immune response in
experimental allergic encephalomyelitis through modula-
tion of regulatory T cells into pathogenic Th17 cells
[43]. Mast cells foster inflammation through the
Figure 5 TNF-a/CD68 macrophages overlie neurons. Confocal microscopy of ALS spinal cord. (A) TNF-a/CD68 (magenta/green) macrophages
overlie many NeuN/DAPI (red/blue) neurons and appear white (*) (40×); (B) Two macrophages (magenta/green) overlie a neuron (red/blue)
(100×); (C) to (F) TNF-a (magenta); CD68 (green); neu-N (red); DAPI (blue).
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Page 9 of 14Figure 6 Fibrillar and APO wild-type SOD-1, and APO and AI mutant forms of SOD-1 induce IL-1b and IL-6. Peripheral blood
mononuclear cells of two sALS patients were stimulated by the indicated SOD-1 proteins and cytokines were measured in the supernatant after
18 h. Note positive dose-response of IL-1b and IL-6 to fibrillar and APO wild-type SOD-1(A, D), and to APO and AI forms of G37R and D101N
SOD-1 (B, C, E, F) (open symbols = patient 1; closed symbols = patient 2).
Figure 7 Stimulation of the supernatant cytokines IL-1b, IL-6, IL-7, IL-10, GM-CSF and TNF-a by stimulation with sham, amyloid-b,A I
WT, AI G37R and fibrillar SOD-1 in sALS patients. Mutant SOD-1 induced 6 cytokines: IL-1b (P = 0.006; AI G37R vs. AI wild type SOD-1);
interleukin-6 (P < 0.001; AI G37R vs. AI wild type SOD-1); IL-7 (P = 0.021; AI G37R vs. AI wild SOD-1); TNF-a (P < 0.001, AI G37R vs. AI wild type
SOD-1); granulocyte-macrophage colony stimulating factor (P = 0.026, AI G37R vs. AI wild type SOD-1), and IL-10 (P = 0.026, AI G37R vs. AI wild
type SOD-1).
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Page 10 of 14production of IL-6 and the shift of regulatory T cells to
TH17 cells [44].
Fibrillar and APO forms of wild type SOD-1, but not
the AI form, induced the key cytokines, IL-1b and IL-6,
indicating their crucial role in inflammation of sALS
patients (Figure 6). These autoantigens are likely present
in the inclusions with non-native/misfolded forms of
SOD-1, which are present in sporadic ALS spinal cords
[4], and might be released from live or dying neurons
[45,46] and be presented to autoimmune T cells by
macrophages and dendritic cells.
Whole-genome expression analysis revealed that sti-
mulation by SOD-1 increased in mononuclear cells of
both patients and controls the transcription of cytokines,
chemokines and matrix metallopeptidases. In patients’
cells, however, the pro-inflammatory cytokines IL-1a
and IL-6 were enhanced more and the anti-inflamma-
tory cytokine IL-10 was enhanced less than in controls’
cells (Figure 8). The chemokines expressed at a high
level even before stimulation include CCL2 (MCP-1),
CXCL1 (GROa), and CXCL3 (GROg). The chemokine
CCL20 (MIP-3a), a chemoattractant for CCR6, the mar-
ker of Th17 cells [47], was increased by SOD-1
stimulation more in patients’ than in controls’ cells.
Matrix metallopeptidase 1, an effector of tissue remodel-
ing [35], and tissue factor pathway inhibitor 2 were
strongly stimulated in patients’ cells, suggesting global
pathology in ALS [48]. In agreement with the constitu-
tive production of IL-17A in PBMC’s, no increase in the
transcription of IL-17A upon 18-hr SOD-1 stimulation
was observed.
Conclusions
On the basis of these and previous observations
[3,14,20], we propose the following immunopathogenesis
of sporadic ALS (Figure 9): (a) aggregated wild type
SOD-1 may induce chemokines and eicosanoids in a
variety of neural cells, such as microglia, astrocytes and
neurons; (b) The chemokines (CXCL1, CXCL3 and
CCL2) and leukotrienes attract monocytes and T cells
into the neuropil; (c) Aggregated SOD-1 stimulates
macrophages and microglia to produce eicosanoids,
tumor necrosis factor-a,I L - 1 b,a n dI L - 6 ,w h i c h( d )s t i -
mulate T cells to produce IL-6, IL-23 and other cyto-
kines and chemokines; (e) IL-1b, IL-6, CCL20 and IL-23
polarize CD8 (and CD4) T cells and mast cells to
Figure 8 Transcriptional upregulation by G37R SOD-1 of cytokines, chemokines, MMP1 and TFPI2. The values after Robust Multi-array
Analysis (RMA) are displayed for patients and control subjects and the ratio of values (patient/control) for each gene is shown. Note the
cytokines (*) increased and those (**) decreased in patients in comparison to controls.
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Page 11 of 14produce IL-17A; (f) CD8 T cells expressing granzyme B
together with macrophages, mast cells, complement,
NO, and other effector mechanisms cause neuronal
apoptosis. Our results show a higher expression of
IL-17A but lower expression of IL-10 in patients than
controls, suggesting that the activation of regulatory T
pathways is suppressed in patients, further suggesting a
higher vulnerability of ALS patients to IL-17A-mediated
damage. The discovery of IL-17A explains the chronic
nature of inflammation in the ALS spinal cord and
offers a new approach to therapy by immune modula-
tion of inflammatory cytokines.
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